HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SVRA
Savara Inc.
There isn't enough reported data to score SVRA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SVRA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SVRA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SVRA PE Valuation
SVRA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SVRA Forward outlook
There aren't enough analyst estimates for SVRA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SVRA on earnings, with more consistent year-over-year improvement.
SVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.61 | -$0.07 |
| Q2 2026 | -$0.58 | -$0.07 |
| Q1 2026 | -$0.56 | -$0.07 |
| Q4 2025 | -$0.53 | -$0.05 |
| Q3 2025 | -$0.54 | -$0.11 |
| Q2 2025 | -$0.51 | -$0.09 |
| Q1 2025 | -$0.49 | -$0.12 |
| Q4 2024 | -$0.48 | -$0.15 |
SVRA is still losing money, but far less than before: $0.61 per share over the past year, against $1.93 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SVRA Quarterly Revenue
SVRA and HIMS do not have enough comparable growth data to identify a winner.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2020 | -1301200% | N/A |
| Q3 2020 | -4213% | N/A |
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SVRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.8M | -$20.3M |
| Q2 2026 | -$30M | -$3.7M |
| Q1 2026 | -$33.1M | -$5.9M |
| Q4 2025 | -$25.1M | -$1.8M |
| Q3 2025 | -$22.5M | +$139K |
| Q2 2025 | -$26.3M | -$3.8M |
| Q1 2025 | -$27.2M | -$6.5M |
| Q4 2024 | -$23.3M | -$7.6M |
SVRA has burned cash in almost every quarter: −$131M over the past year, against −$99M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SVRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +650K shares |
| 1 year | +17% | +37.8M shares |
| 3 years | +55% | +89.9M shares |
| 5 years | +67% | +102M shares |
| Available history | +343% | +197M shares |
SVRA has 254M diluted shares, up 17% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SVRA Net Leverage
SVRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.0 | Neutral |
| Stochastic | 35.5 | Neutral |
SVRA's weekly RSI is 44 (neutral) and its Stochastic is 36 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SVRA PE vs Healthcare Sector
SVRA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.72 | 0% above |
| 20 week MA | $5.23 | 9.8% below |
| 50 week MA | $5.44 | 13% below |
| 100 week MA | $4.26 | 11% above |
| 200 week MA | $3.98 | 19% above |
SVRA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.73 | $1.31 | -24% |
| 2021 | $1.31 | $1.29 | -1.5% |
| 2022 | $1.29 | $1.50 | +16% |
| 2023 | $1.50 | $4.70 | +213% |
| 2024 | $4.70 | $3.15 | -33% |
| 2025 | $3.15 | $6.45 | +105% |
| 2026 YTD | $6.45 | $4.72 | -27% |
SVRA has the edge over HIMS on returns for 2026, with the stronger performance.